FDA Issues Recall Information for Hologic BioZorb 3D Bioabsorbable Implantable Markers

News Summary

July 6, 2026 — FDA has published recall information for Hologic BioZorb 3D bioabsorbable implantable markers. FDA classified the recall of Hologic BioZorb Marker and BioZorb LP Marker as the most serious type of recall (Class I), involving complications associated with implantable markers and patient risk.

Source

Source agency: FDA (CDRH)

Official page date: June 30, 2026

Article publication date: July 6, 2026

Source page: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/implantable-marker-recall-hologic-removes-biozorb-marker-and-biozorb-lp-marker

This article is translated and organized from the main text of the official FDA CDRH page dated June 30, 2026. Source: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/implantable-marker-recall-hologic-removes-biozorb-3d-bioabsorbable-markers-due-risk-patient

Full Translation of Core Content

The FDA page states that Hologic is removing products related to BioZorb Marker and BioZorb LP Marker. FDA has classified the matter as the most serious type of recall because of complications associated with the implantable markers and patient risk.

For implantable or absorbable products, post-market risk often does not come from a single performance indicator alone. It is also associated with materials, biocompatibility, degradation performance, implant location, individual patient differences, physician use technique, and long-term follow-up data. The purpose of FDA public recall information is to enable healthcare institutions, patients, and industry to understand potential risks in a timely manner and take appropriate action.

For exporting companies, when implant-related products enter markets such as the United States, the European Union, and Australia, particular attention should be paid to risk management, clinical evidence, post-market clinical follow-up, complaint trends, and recall preparedness.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Affairs believes that the value of FDA recall or correction information is not limited to reminding companies about a particular brand or model. It reflects the real review logic that mature markets apply to post-market system capability.

The focus of regulators is not whether a company has written complaint handling, recall, and CAPA procedures. The focus is whether the company can, after an issue occurs, rapidly identify affected products, define the risk level, notify customers, track batches, control inventory, update instructions for use, and implement corrective actions across design, production, suppliers, and user training.

For Chinese medical device companies, if a product is an active device, implantable product, infusion system, life-support device, home monitoring device, or software-controlled device, FDA public recall cases should be included in the post-market risk library. Before registration, companies should not only prepare performance testing and technical documentation; they should also establish in advance complaint classification, adverse event assessment, field safety corrective action, recall simulation, distributor notification, and overseas customer response mechanisms. Otherwise, even if initial registration is successful, insufficient post-market response capability after market entry may affect brand credibility and subsequent registration maintenance.

AIMEILI recommends that companies establish an internal similar-product recall review table. It should record, item by item, the source of the issue, potential harm, regulatory classification, company actions, user actions, and the corresponding risks for the company’s own products. This action can directly feed back into risk management, PMS plans, labels and instructions for use, human factors validation, and the CAPA system. It is a key step for companies going global to move from a certificate-obtaining mindset to a continuous compliance mindset.

Business Impact

This update may affect a company’s assessment of registration pathways, technical file preparation, labels and instructions for use, quality system records, or post-market maintenance arrangements. Companies should conduct an internal assessment based on the target market, product risk class, existing certificates, and sales plans, rather than treating regulatory news as general information only.

For manufacturers, distributors, CROs, and regulatory affairs teams, the case reinforces that recall readiness is part of market access capability. It should be planned before submission and tested through mock recall and customer notification exercises, not created only after a regulatory action.

Recommended Compliance Actions

• Confirm whether the update affects existing registration pathways, certificate maintenance, or post-market obligations.
• Verify technical files, labels and instructions for use, quality system arrangements, and local responsible entity arrangements for target countries.
• Establish change impact assessments and regulatory update tracking records for marketed products.
• Where necessary, archive the official source text, English analysis, and internal action items to support future audits and project reviews.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Scope: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal opinions.